PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...
Please provide your email address to receive an email when new articles are posted on . Leqembi Iqlik is the first approved in-home anti-amyloid injectable for early Alzheimer’s disease. Patients ...
A subcutaneous injection that can administer an immunotherapy in 1–2 minutes using domestic technology has been developed and approved in the United States. Immunotherapies are usually given ...
KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J., September 19, ...
The first immune checkpoint inhibitor that can be administered via subcutaneous injection in just 1 to 2 minutes has emerged. Alteogen announced on the 20th that its partner Merck (MSD) in the U.S.
FDA Approves Subcutaneous Leqembi for Treatment of Early Alzheimer Disease By Stephanie Brown HealthDay ReporterTUESDAY, Sept. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...
In September 2025, Merck received FDA approval for KEYTRUDA QLEX, a subcutaneous version of its flagship cancer therapy, allowing for one- to two-minute administration across 38 solid tumor ...
FORT LAUDERDALE, Fla. — In this Healio Video Perspective, Michael A. Singer, MD, discusses promising results for migaldendranib for the treatment of wet age-related macular degeneration and diabetic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback